PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. raised its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 14.0% during the third quarter, HoldingsChannel reports. The firm owned 54,014 shares of the biopharmaceutical company’s stock after buying an additional 6,634 shares during the period. Harbor Capital Advisors Inc.’s holdings in PTC Therapeutics were worth $2,004,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of PTCT. Janus Henderson Group PLC boosted its holdings in shares of PTC Therapeutics by 40.5% in the first quarter. Janus Henderson Group PLC now owns 3,669,816 shares of the biopharmaceutical company’s stock valued at $106,744,000 after acquiring an additional 1,057,223 shares in the last quarter. Vanguard Group Inc. increased its position in shares of PTC Therapeutics by 6.5% in the first quarter. Vanguard Group Inc. now owns 9,369,014 shares of the biopharmaceutical company’s stock valued at $272,545,000 after buying an additional 568,171 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of PTC Therapeutics by 21.3% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,605,841 shares of the biopharmaceutical company’s stock valued at $46,714,000 after buying an additional 282,422 shares in the last quarter. Armistice Capital LLC raised its stake in shares of PTC Therapeutics by 2.9% during the 2nd quarter. Armistice Capital LLC now owns 6,962,227 shares of the biopharmaceutical company’s stock worth $212,905,000 after buying an additional 198,227 shares during the last quarter. Finally, Ensign Peak Advisors Inc boosted its position in shares of PTC Therapeutics by 650.9% in the 2nd quarter. Ensign Peak Advisors Inc now owns 208,302 shares of the biopharmaceutical company’s stock worth $6,370,000 after buying an additional 180,561 shares in the last quarter.

PTC Therapeutics Stock Down 0.2 %

NASDAQ:PTCT opened at $40.39 on Tuesday. The company has a market cap of $3.11 billion, a P/E ratio of -6.40 and a beta of 0.63. The firm’s 50 day moving average is $36.81 and its two-hundred day moving average is $34.63. PTC Therapeutics, Inc. has a fifty-two week low of $18.15 and a fifty-two week high of $43.40.

PTC Therapeutics (NASDAQ:PTCT) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.16). The company had revenue of $186.70 million during the quarter, compared to analysts’ expectations of $192.12 million. Research analysts forecast that PTC Therapeutics, Inc. will post -5.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on PTCT shares. Cantor Fitzgerald restated an “overweight” rating and set a $64.00 target price on shares of PTC Therapeutics in a research report on Tuesday, September 17th. Robert W. Baird restated an “outperform” rating and set a $44.00 price objective on shares of PTC Therapeutics in a research report on Tuesday, October 8th. Baird R W raised PTC Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 4th. Morgan Stanley boosted their target price on shares of PTC Therapeutics from $32.00 to $45.00 and gave the company an “equal weight” rating in a research note on Friday, October 11th. Finally, UBS Group began coverage on shares of PTC Therapeutics in a research note on Monday, August 26th. They set a “buy” rating and a $47.00 price target on the stock. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, PTC Therapeutics has an average rating of “Hold” and an average price target of $40.08.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.